Barnés et al. 10.1073/pnas.0509579102.

Supporting Information

Files in this Data Supplement:

Supporting Table 3
Supporting Figure 4
Supporting Figure 5
Supporting Table 4
Supporting Table 5
Supporting Figure 6
Supporting Figure 7
Supporting Table 6
Supporting Figure 8




Supporting Figure 4

Fig. 4. Hierarchical clustering of tissue samples (with respect to expression of 7,815 genes) by using a variety of methods for building the dendrograms. (a) Single linkage. (b) Complete linkage. (c) Increase in sum of squares. (d) Sum of squares. (e) Density (k = 3). (f) Density (k = 16). (g) Mean proximity. Clustering was based on the 63 × 63 distance matrix for the 63 tissue samples. Gene expression "signal" values were log2-transformed, and the samples were standardized to the z score before calculating the squared Euclidean distance De or Dc = | r – 1|, where r = Pearson correlation coefficient, as distance metric. Clustering was performed by using clustan 6.0 (Clustan, Ltd., Edinburgh). For both standardized (z score) and nonstandardized data, analysis based on De or Dc resulted in the same clusters, including coclustering of hemangioma samples (H)-placental samples (P). Dendrograms were identical for De and Dc only with the standardized data, indicating that the z score transformation provided robustness with respect to the choice of distance metric. Shown above are the dendrograms by using De as distance metric with standardized data.





Fig. 5. Self-organizing maps of all samples, visualized by using gene expression data inspection software gedi (1). Gene density map and parameters, calculated by using 63 samples and 7,815 genes. Individual samples grouped by tissue type are shown in individual columns for facile comparison.

1. Eichler, G. S., Huang, S. & Ingber, D. E. (2003) Bioinformatics 19, 2321–2322.





Fig. 6. Jackknife analysis: correlation coefficient of EC-associated set after removing a single probe (a and b) or a single gene (c and d). Comparison of average correlation coefficient of all same-tissue pair comparisons (X-X) and different-tissue pair comparisons (X-Y) to the correlation coefficient of H-P. Note that in every case, the correlation coefficient of H-P is comparable to that of X-X. Xn-Xn and Xn-Yn correspond to comparisons of normal tissue pairs only (a and c), whereas Xa-Xa and Xa-Ya correspond to comparisons of all (normal and diseased) tissue pairs (b and d).





Fig. 7. Genes differentially expressed in placenta and hemangioma relative to X control tissues. X = 4 normal and 4 diseased control tissues (red subset), or 4 normal control tissues only (gray subset), and H/X ³ 3 and P/X ³ 3. Normal control tissues include brain, lung, muscle, skin, and diseased control tissues include sclerodermic skin (Sc Skin) and pulmonary tumors: lung carcinoid (Car Lung), squamous cell carcinoma (Sq Lung), and small cell carcinoma (SmC Lung). Individual samples represented in each box. (a) Color map of individual normalized signal values. (b) Significance of signal values, indicated by presence/absence of call (Affymetrix).





Fig. 8. Hemangioma and placental gene expression of 17-b hydroxysteroid dehydrogenase type II (17HSDb2), insulin-like growth factor II (IGF2), and tissue factor pathway inhibitor 2 (TFPI2) by quantitative RT-PCR. EC and fibroblasts (FB) are from hemangioma (hem EC and hem FB), placenta (plac EC and plac FB), human umbilical vein (HUVEC), and neonatal foreskin (HMVEC or foreskin FB).





Table 3. Data from human tissues used in array comparison (2 pages)

Tissue

Sample identifier

Sample identifier in ref.

Age/gender

Ref.

Brain

B 1

B_26M

26/M

1

Brain

B 2

B_36F

36/F

1

Brain

B 3

B_37M

37/M

1

Brain

B 4

B_38F

38/F

1

Hemangioma

H 1

HEM005

6m/M

 

Hemangioma

H 2

HEM016

7m/F

 

Hemangioma

H 3

HEM019

4m/F

 

Hemangioma

H 4

HEM020

5m/M

 

Hemangioma

H 5

HEM021

2m/F

 

Hemangioma

H 6

HEM012

5m/F

 

Lung

L 2

NL1884

n.a.

2

Lung

L 4

NL6084

n.a.

2

Lung

L 6

NL3681

n.a.

2

Lung

L 8

NL1179

n.a.

2

Lung

L 10

NL1675

n.a.

2

Lung

L 12

NL268n1

n.a.

2

Lung

L 14

NL1698

n.a.

2

Lung

L 16

NL6853

n.a.

2

Muscle

M 1

T147

4yr/F

3

Muscle

M 2

T146

1yr/M

3

Muscle

M 3

T141

2yr/M

3

Muscle

M 4

T148

5yr/F

3

Muscle

M 5

T142

2yr/F

3

Muscle

M 6

T144

6yr/M

3

Placenta

P 1

TPV3

Term/n.d.

 

Placenta

P 2

TPV4

Term/n.d.

 

Placenta

P 3

TPV5

Term/n.d.

 

Placenta

P 4

TPV6

Term/n.d

 

Placenta

P 5

TPV7

Term/n.d

 

Placenta

P 6

TPV1

Term/n.d

 

Placenta

P 7

TPV2

Term/n.d

 

Skin

S 1A

1.N. Nor1-FA

39y/M

4

Skin

S 1B

2.O. Nor1-B

39y/M

4

Skin

S 2A

3.P. Nor2-FA

58y/F

4

Skin

S 2B

4.Q. Nor2-B

58y/F

4

Skin

S 3A

5.R. Nor3-FA

58y/F

4

Skin

S 3B

6.T. Nor4-FA

41y/F

4

Skin

S 4A

7.U. Nor4-B

41y/F

4

Squamous lung

Sq 2

SQ6T1

n.a.

2

Squamous lung

Sq 4

SQ3624

n.a.

2

Squamous lung

Sq 6

SQ1174

n.a.

2

Squamous lung

Sq 8

SQ4T1

n.a.

2

Squamous lung

Sq 10

SQ8T1

n.a.

2

Squamous lung

Sq 12

SQ6147

n.a.

2

Carcinoid lung

Car 2

COID13T1

n.a.

2

Carcinoid lung

Car 4

COID6T1

n.a.

2

Carcinoid lung

Car 6

COID16T1

n.a.

2

Carcinoid lung

Car 8

COID10T1

n.a.

2

Carcinoid lung

Car 10

COID9T1

n.a.

2

Carcinoid lung

Car 12

COID4518

n.a.

2

Small cell

SmC 1

SMCL9T1

n.a.

2

Small cell

SmC 2

SMCL5937

n.a.

2

Small cell

SmC 3

SMCL4T1

n.a.

2

Small cell

SmC 4

SMCL3T1

n.a.

2

Small cell

SmC 5

SMCL301

n.a.

2

Small cell

SmC 6

SMCL8T1

n.a.

2

Scleroderma

Sc 1A

1.F. SSc1-FA

41y/M

4

Scleroderma

Sc 1B

2.G. SSc1-B

41y/M

4

Scleroderma

Sc 2A

3.H. SSc2-FA

54y/M

4

Scleroderma

Sc 2B

4.I. SSc2-B

54y/M

4

Scleroderma

Sc 3A

5.J. SSc3-FA

62y/F

4

Scleroderma

Sc 3B

6.K. SSc3-B

62y/F

4

Scleroderma

Sc 4A

7.L. SSc4-FA

58y/F

4

Scleroderma

Sc 4B

8.M. Nor1-FA

39y/M

4

n.a., not available; muscle, normal skeletal muscle from quadriceps; brain, normal brain from frontal lobe; hemangioma, infantile hemangioma from cutaneous lesions; placenta, normal term placentas from chorionic villi section (Placenta 1–5 and 7) or from chorionic plate (Placenta 6).

1. Lu, T., Pan, Y., Kao, S. Y., Li, C., Kohane, I., Chan, J. & Yankner, B. A. (2004) Nature 429, 883–891.

2. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) Proc. Natl. Acad. Sci. USA 98, 13790–13795.

3. Sanoudou, D., Haslett, J. N., Kho, A. T., Guo, S., Gazda, H. T., Greenberg, S. A., Lidov, H. G. W., Kohane, I. S., Kunkel, L. M. & Beggs, A. H. (2003) Proc. Natl. Acad. Sci. USA 100, 4666–4671.

4. Whitfield, M. L., Finlay, D. R., Murray, J. I., Troyanskaya, O. G., Chi, J.-T., Pergamenschikov, A., McCalmont, T. H., Brown, P. O., Botstein, D. & Connolly, M. K. (2003) Proc. Natl. Acad. Sci. USA 100, 12319–12324.





Table 4. Differentially expressed endothelial cell genes used in Fig. 3

U95Av/2

Accession no.

Gene name

Symbol

Fold Diff.*

1733_at

AA424833

Bone morphogenetic protein 6

BMP6

6.5

39279_at

AA424833

Bone morphogenetic protein 6

BMP6

6.5

35036_at

AA150505

Complement component 1, q subcomponent, recept. 1

C1qR(p)

29.1

37196_at

H02884

Cadherin 5, type 2, VE-cadherin

CDH5

23.5

36638_at

AA598794

Connective tissue growth factor

CTGF

4.2

587_at

N93476

Endothelial differentiation, sphingolipid G-protein-coupled recept, 1

EDG1

10.4

32551_at

AA875933

EGF-containing fibulin-like extracellular matrix protein 1

EFEMP1

25

33534_at

W46577

Endothelial cell-specific molecule 1

ESM1

27.6

1954_at

AA026831

Kinase insert domain receptor (a type III recept. Tyr kinase)

KDR

5.5

690_s_at

AA026831

Kinase insert domain receptor (a type III recept. Tyr kinase)

KDR

5.5

38351_at

AA418988

KIAA1462

KIAA1462

5

37671_at

Z99289

Laminin a 4 chain

LAMA4

4.9

36065_at

AF064493

LIM domain binding 2

LDB2

5.9

797_at

AI888888

Melanoma cell adhesion molecule

MCAM

11.6

36683_at

AA155913

Matrix Gla protein

MGP

5.6

35664_at

AA423867

Multimerin 1

MMRN1

48.3

1245_i_at

AF092132

p21 (CDKN1A)-activated kinase 2

PAK2

4.5

1560_g_at

AF092132

p21-activated protein kinase (Pak2)

PAK2

4.5

34329_at

AF092132

p21 (CDKN1A)-activated kinase 2

PAK2

4.5

268_at

M28526

Platelet/endothelial cell adhesion molecule-1

PECAM1

18.8

37397_at

M28526

Platelet/endothelial cell adhesion molecule-1

PECAM1

18.8

37398_at

M28526

Platelet/endothelial cell adhesion molecule-1

PECAM1

18.8

40434_at

N64508

Podocalyxin-like protein

PODXL

8.2

41577_at

AI279830

Protein phosphatase 1, regulatory (inhibitor) subunit 16B

PPP1R16B

6.9

438_at

W68141

Protein kinase, cAMP-dependent, catalytic, a

PRKACA

5.2

568_at

W68141

Protein kinase, cAMP-dependent, catalytic, a

PRKACA

5.2

569_g_at

W68141

Protein kinase, cAMP-dependent, catalytic, a

PRKACA

5.2

647_at

T47442

Protein C receptor, endothelial (EPCR)

PROCR

5

607_s_at

AA485883

von Willebrand factor

vWF

10

*Data from Ho, M., Yang, E., Matcuk, G., Deng, D., Sampas, N., Tsalenko, A., Tabibiazar, R., Zhang, Y., Chen, M., Talbi, S., et al. (2003) Physiol. Genomics 13, 249–262.

Average of all PECAM1 transcripts (8.8- to 55.5-fold change).



Table 5. Oligonucleotides used for Quantitative RT-PCR

Target

Name

Sequence 5'-3'

Product size, bp

Annealing temp., ºC

TFPI2

Forward Reverse

CGGATTGAGAACAGGTTTCCAGATGAAGC AATAGCGAGTCACATTGGCAGAGCACAGTC

124

60

HSD17B2

Forward Reverse

GCCGTGAACTTCTTTGGAACTGTGGAGGTC GCCGCCTTTGATGAGCCATAAGATGCC

146

63

IGF2

Forward Reverse

TCGCCGGCTTCCAGACACCAAT CGGTAAGCAGCAATGCAGCACGAG

100

60

b2M

Forward Reverse

CAATCCAAATGCGGCATCTTCAAAC GAATGGAGAGAGAATTGAAAAAGTGGAGCA

217

60 or 63

Primer sequences were designed in oligo 5.0 and obtained from Integrated DNA Technologies. RNA from normal samples (0.2–0.5 mg) was reverse-transcribed to cDNA and amplified by real-time quantitative PCR in 40 cycles by using Quantitect SYBR Green RT-PCR kit (Qiagen). PCR amplification reactions were performed and analyzed in an option 2.0 detection system (MJ Research) or in a Mx4000 multiplex quantitative PCR system (Stratagene).